We use third-party cookies in order to personalize your site experience. See our Privacy Policy.

Technology thesis · Biotechnology & Health

high conviction growth

Protein engineering

Generative protein design has crossed into the clinic: AI-engineered antibody GB-0895 reached Phase 3 in late 2025 and RFdiffusion3 made atom-level de novo design routine.

Position maintained continuously · last reviewed Jun 24, 2026

The thesis

Core thesis

David Baker (Nobel 2024, Institute for Protein Design) pioneered de novo protein design. AlphaFold predicted structures; Baker's work creates new structures from scratch. Applications: novel enzymes for manufacturing, protein therapeutics, biosensors, and materials. The dual-use concern: the same tools that design beneficial proteins can theoretically design harmful ones.

State of the art (2026)

Protein engineering in 2026 is defined by three converging fronts. Generation: David Baker’s Institute for Protein Design released RFdiffusion3 in December 2025 – an all-atom diffusion model that designs binders to DNA, ligands and enzyme active sites, alongside EvolutionaryScale’s ESM3 and DeepMind’s AlphaFold 3 for structure and interactions. Clinic: Generate Biomedicines began global Phase 3 trials of GB-0895, an AI-engineered long-acting anti-TSLP antibody for severe asthma, in late 2025 – among the first generative-AI molecules to reach Phase 3. Industry: Isomorphic Labs runs multi-billion-dollar pharma deals, while Codexis, Arzeda and Novonesis push designed enzymes into manufacturing. The open question is whether fully de novo proteins, not just optimised antibodies, deliver clinical efficacy.

The rest of the file

Everything below is live inside CanaryIQ

The full analysis behind the verdict — the structure is real; the content unlocks when you log in.

Signal stack

Evidence stacked leading → lagging

8 signals
talent
research
patent
operational
market

Technology-native KPIs

Metrics that predict trajectory, tracked over time

3 tracked
AI-designed protein success rate
De novo protein design cycle time
Enzyme engineering pipeline candidates

Landscape map

Who builds what — and who depends on whom

70 players · 5 layers

Catalyst calendar

Dated events that will move the position

3 ahead

Watchlists

Companies, people and papers — each with a remove-by condition

19 · 3
Companies · 19
People · 3

Decision frameworks

The same call, framed for your desk

Locked
Public Equity
Corporate Leader

Thesis changelog

When our view changed, and why

5 updates

Change our mind

3 disconfirming conditions

The rest is inside

You've read the verdict. The file is much deeper.

The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on Protein engineering has changed — all live inside CanaryIQ.